Gamida Cell Ltd. GMDA
0.03 0.00 (+0.00%)
At closeJun 17, 2025, 4:00 PM EDT
0.0327 Day range 0.0395
52-week range unavailable
- Market cap
- 4.34M
- Revenue (ttm)
- 673.00K
- Shares out
- 132.64M
- Forward P/E
- -0.06
- Volume
- 19.05M
- Open
- 0.0395
- Previous close
- 0.0327
- Day's range
- 0.0327 – 0.0395
- Beta
- 1.03
- Analysts
- Buy
- Price target
- 4.00 (+12132.4%)
- Earnings date
- May 20, 2024
No chart data for this range yet.
Key statistics
- Enterprise value
- 70.28M
- PEG ratio
- 0.00
- Price / sales
- 6.44
- Price / book
- 10.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -54.19M
- Total cash
- 60.43M
- Total debt
- 85.22M
- Return on equity
- -1103.79%
- Short % of float
- 7.90%
- 50-day average
- 0.242678
- 200-day average
- 0.627926
Analyst view
Consensus: buy
Buy
Price target (mean) 4.00 +12132.4% upside
Now 0.0327
- Target (low)
- 2.00
- Target (mean)
- 4.00
- Target (high)
- 6.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
May 20, 2024
Expected May 20, 2024. Consensus EPS estimate -0.13.
Financials — quick view
GMDA Revenue — quarterly 1.11M
GMDA Net income — quarterly -8.84M
GMDA EPS — quarterly -0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 20, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 27, 2024 | Dec 1, 2023 | -0.13 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -0.15 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -0.18 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -0.27 | — | — | — |
| Mar 27, 2023 | Dec 1, 2022 | -0.24 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 29, 2024 | JMP Securities | down | Market Outperform | Market Perform |
| Dec 5, 2023 | Needham | reit | Buy | Buy |
| Nov 15, 2023 | Piper Sandler | main | Overweight | Overweight |
| Nov 15, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 28, 2023 | JMP Securities | reit | Market Outperform | Market Outperform |
| Aug 16, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Gamida Cell Ltd.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- gamida-cell.com
News
Gamida Cell Presents Positive Initial Results on Treating Severe Aplastic Anemia (SAA) with Omidubicel 
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development 
Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management 
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket 
Why Is Gamida Cell (GMDA) Stock Down 82% Today? 
Gamida Cell Ltd. (GMDA) Q4 2023 Earnings Call Transcript 
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update 
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
Your note
Sign in to keep a note on GMDA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS JULIAN | Director | Stock Award(Grant) | Jan 30, 2024 | 423,750 |
| BLANK JEREMY | Director | Stock Award(Grant) | Aug 10, 2023 | 5,173,470 |
| BORRELLO IVAN M | Director | Stock Award(Grant) | Jan 30, 2024 | 232,300 |
| JENKINS ABIGAIL L | Chief Executive Officer | Stock Award(Grant) | Oct 18, 2023 | 266,129 |
| KORFIN MICHELE ILENE | Chief Operating Officer | Stock Award(Grant) | Jan 30, 2024 | 702,981 |
| MOCH KENNETH I | Director | Stock Award(Grant) | Jan 30, 2024 | 232,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 5.22% | 8,042,172 | 262.98K | Dec 30, 2023 |
| Levin Capital Strategies, LP | 3.91% | 6,023,629 | 196.97K | Dec 30, 2023 |
| Meitav Investment House Ltd. | 2.37% | 3,655,158 | 119.52K | Dec 30, 2023 |
| Millennium Management Llc | 1.67% | 2,568,866 | 84.00K | Dec 30, 2023 |
| Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD | 1.44% | 2,211,981 | 72.33K | Dec 30, 2023 |
| ARK Investment Management, LLC | 1.39% | 2,144,422 | 70.12K | Dec 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Variable Insurance Products Fund-Growth Portfolio | 1.44% | 2,212,268 | 72.34K | Feb 28, 2024 |
| Fidelity Capital Appreciation Fund | 1.41% | 2,169,053 | 70.93K | Feb 28, 2024 |
| Fidelity Advisor Equity Growth Fund | 1.23% | 1,892,438 | 61.88K | Feb 28, 2024 |
| Fidelity Growth Discovery Fund | 0.65% | 993,684 | 32.49K | Feb 28, 2024 |
| Pacific Select Fund-Large Cap Growth Portfolio | 0.22% | 334,500 | 10.94K | Dec 30, 2023 |
| iShares Micro Cap ETF | 0.18% | 272,867 | 8.92K | Jan 30, 2024 |